{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:11:44Z","timestamp":1788880304967,"version":"build-2803163510"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-026-05380-1","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:44:45Z","timestamp":1788878685000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["APOL1 kidney disease: a critical narrative review of molecular mechanisms, clinical heterogeneity, and the emerging therapeutic landscape"],"prefix":"10.1007","author":[{"given":"Nishant","family":"Dogra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayank","family":"Baranwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shad","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravin","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahendra Singh","family":"Ashawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"issue":"2","key":"5380_CR1","doi-asserted-by":"publisher","first-page":"294","DOI":"10.2215\/CJN.15161219","volume":"16","author":"DJ Friedman","year":"2021","unstructured":"Friedman DJ, Pollak MR (2021) APOL1 nephropathy: from genetics to clinical applications. Clin J Am Soc Nephrol 16(2):294\u2013303. https:\/\/doi.org\/10.2215\/CJN.15161219","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"5380_CR2","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.kint.2021.03.013","volume":"99","author":"BI Freedman","year":"2021","unstructured":"Freedman BI, Kopp JB, Sampson MG, Susztak K (2021) APOL1 at 10 years: progress and next steps. Kidney Int 99(6):1296\u20131302. https:\/\/doi.org\/10.1016\/j.kint.2021.03.013","journal-title":"Kidney Int"},{"issue":"3","key":"5380_CR3","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/MNH.0000000000001068","volume":"34","author":"MR Pollak","year":"2025","unstructured":"Pollak MR, Friedman DJ (2025) APOL1-associated kidney disease: modulators of the genotype-phenotype relationship. Curr Opin Nephrol Hypertens 34(3):191\u2013198. https:\/\/doi.org\/10.1097\/MNH.0000000000001068","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"5993","key":"5380_CR4","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1126\/science.1193032","volume":"329","author":"G Genovese","year":"2010","unstructured":"Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob AL, Bernhardy AJ, Hicks PJ, Nelson GW, Vanhollebeke B, Winkler CA, Kopp JB, Pays E, Pollak MR (2010) Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science (New York, NY) 329(5993):841\u2013845. https:\/\/doi.org\/10.1126\/science.1193032","journal-title":"Science (New York, NY)"},{"issue":"3","key":"5380_CR5","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00439-010-0861-0","volume":"128","author":"S Tzur","year":"2010","unstructured":"Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, Tarekegn A, Bekele E, Bradman N, Wasser WG, Behar DM, Skorecki K (2010) Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 128(3):345\u2013350. https:\/\/doi.org\/10.1007\/s00439-010-0861-0","journal-title":"Hum Genet"},{"issue":"20","key":"5380_CR6","doi-asserted-by":"publisher","first-page":"E2130","DOI":"10.1073\/pnas.1400699111","volume":"111","author":"R Thomson","year":"2014","unstructured":"Thomson R, Genovese G, Canon C, Kovacsics D, Higgins MK, Carrington M, Winkler CA, Kopp J, Rotimi C, Adeyemo A, Doumatey A, Ayodo G, Alper SL, Pollak MR, Friedman DJ, Raper J (2014) Evolution of the primate trypanolytic factor APOL1. Proc Natl Acad Sci U S A 111(20):E2130\u2013E2139. https:\/\/doi.org\/10.1073\/pnas.1400699111","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"5380_CR7","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.coi.2009.05.024","volume":"21","author":"E Pays","year":"2009","unstructured":"Pays E, Vanhollebeke B (2009) Human innate immunity against African trypanosomes. Curr Opin Immunol 21(5):493\u2013498. https:\/\/doi.org\/10.1016\/j.coi.2009.05.024","journal-title":"Curr Opin Immunol"},{"issue":"11","key":"5380_CR8","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1016\/j.ekir.2023.08.028","volume":"8","author":"G Vasquez-Rios","year":"2023","unstructured":"Vasquez-Rios G, De Cos M, Campbell KN (2023) Novel therapies in APOL1-mediated kidney disease: from molecular pathways to therapeutic options. Kidney Int Reports 8(11):2226\u20132234. https:\/\/doi.org\/10.1016\/j.ekir.2023.08.028","journal-title":"Kidney Int Reports"},{"issue":"5","key":"5380_CR9","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.kint.2025.05.017","volume":"108","author":"AO Ojo","year":"2025","unstructured":"Ojo AO, Adu D, Bramham K, Freedman BI, Gbadegesin RA, Ilori TO, Jefferson N, Olabisi OA, Susztak K, Young BA, Cheung M, King JM, Grams ME, Jadoul M, Ulasi II, Conference Participants (2025) APOL1 kidney disease: conclusions from a kidney disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 108(5):763\u2013779. https:\/\/doi.org\/10.1016\/j.kint.2025.05.017","journal-title":"Kidney Int"},{"issue":"4","key":"5380_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.15171\/jrip.2019.57","volume":"8","author":"M Akhavan Sepahi","year":"2019","unstructured":"Akhavan Sepahi M, Bhaskar LVKS, Tolouian A, Tolouian R (2019) Apolipoprotein L1 associated nephropathy; an overview. J Renal Inj Prev 8(4):311\u2013315. https:\/\/doi.org\/10.15171\/jrip.2019.57","journal-title":"J Renal Inj Prev"},{"issue":"1","key":"5380_CR11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev-physiol-021119-034345","volume":"82","author":"DJ Friedman","year":"2020","unstructured":"Friedman DJ, Pollak MR (2020) APOL1 and kidney disease: from genetics to biology. Annu Rev Physiol 82(1):323\u2013342. https:\/\/doi.org\/10.1146\/annurev-physiol-021119-034345","journal-title":"Annu Rev Physiol"},{"issue":"9","key":"5380_CR12","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1073\/pnas.1421953112","volume":"112","author":"R Thomson","year":"2015","unstructured":"Thomson R, Finkelstein A (2015) Human trypanolytic factor APOL1 forms pH-gated cation-selective channels in planar lipid bilayers: relevance to trypanosome lysis. Proc Natl Acad Sci U S A 112(9):2894\u20132899. https:\/\/doi.org\/10.1073\/pnas.1421953112","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"5380_CR13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/ndt\/gfu391","volume":"31","author":"E Kruzel-Davila","year":"2016","unstructured":"Kruzel-Davila E, Wasser WG, Aviram S, Skorecki K (2016) APOL1 nephropathy: from gene to mechanisms of kidney injury. Nephrol Dial Transplant 31(3):349\u2013358. https:\/\/doi.org\/10.1093\/ndt\/gfu391","journal-title":"Nephrol Dial Transplant"},{"issue":"5733","key":"5380_CR14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1126\/science.1114566","volume":"309","author":"D P\u00e9rez-Morga","year":"2005","unstructured":"P\u00e9rez-Morga D, Vanhollebeke B, Paturiaux-Hanocq F, Nolan DP, Lins L, Hombl\u00e9 F, Vanhamme L, Tebabi P, Pays A, Poelvoorde P, Jacquet A, Brasseur R, Pays E (2005) Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. Science (New York, NY) 309(5733):469\u2013472. https:\/\/doi.org\/10.1126\/science.1114566","journal-title":"Science (New York, NY)"},{"key":"5380_CR15","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.51185","volume":"9","author":"JA Giovinazzo","year":"2020","unstructured":"Giovinazzo JA, Thomson RP, Khalizova N, Zager PJ, Malani N, Rodriguez-Boulan E, Raper J, Schreiner R (2020) Apolipoprotein L-1 renal risk variants form active channels at the plasma membrane driving cytotoxicity. Elife 9:e51185. https:\/\/doi.org\/10.7554\/eLife.51185","journal-title":"Elife"},{"issue":"1","key":"5380_CR16","doi-asserted-by":"publisher","first-page":"F1","DOI":"10.1152\/ajprenal.00426.2018","volume":"316","author":"LA Bruggeman","year":"2019","unstructured":"Bruggeman LA, O\u2019Toole JF, Sedor JR (2019) APOL1 polymorphisms and kidney disease: loss-of-function or gain-of-function? Am J Physiol Renal Physiol 316(1):F1\u2013F8. https:\/\/doi.org\/10.1152\/ajprenal.00426.2018","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"5380_CR17","doi-asserted-by":"publisher","first-page":"134","DOI":"10.34067\/KID.0002482020","volume":"2","author":"SM Madhavan","year":"2020","unstructured":"Madhavan SM, Buck M (2020) The relationship between APOL1 structure and function: clinical implications. Kidney360 2(1):134\u2013140. https:\/\/doi.org\/10.34067\/KID.0002482020","journal-title":"Kidney360"},{"issue":"6","key":"5380_CR18","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.semnephrol.2017.07.002","volume":"37","author":"E Kruzel-Davila","year":"2017","unstructured":"Kruzel-Davila E, Wasser WG, Skorecki K (2017) APOL1 nephropathy: a population genetics and evolutionary medicine detective story. Semin Nephrol 37(6):490\u2013507. https:\/\/doi.org\/10.1016\/j.semnephrol.2017.07.002","journal-title":"Semin Nephrol"},{"issue":"5","key":"5380_CR19","doi-asserted-by":"publisher","first-page":"603","DOI":"10.5301\/jn.5000179","volume":"25","author":"WG Wasser","year":"2012","unstructured":"Wasser WG, Tzur S, Wolday D, Adu D, Baumstein D, Rosset S, Skorecki K (2012) Population genetics of chronic kidney disease: the evolving story of APOL1. J Nephrol 25(5):603\u2013618. https:\/\/doi.org\/10.5301\/jn.5000179","journal-title":"J Nephrol"},{"issue":"8","key":"5380_CR20","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.molmed.2018.05.008","volume":"24","author":"P Beckerman","year":"2018","unstructured":"Beckerman P, Susztak K (2018) APOL1: the balance imposed by infection, selection, and kidney disease. Trends Mol Med 24(8):682\u2013695. https:\/\/doi.org\/10.1016\/j.molmed.2018.05.008","journal-title":"Trends Mol Med"},{"issue":"4","key":"5380_CR21","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/nrneph.2013.34","volume":"9","author":"G Genovese","year":"2013","unstructured":"Genovese G, Friedman DJ, Pollak MR (2013) APOL1 variants and kidney disease in people of recent African ancestry. Nat Rev Nephrol 9(4):240\u2013244. https:\/\/doi.org\/10.1038\/nrneph.2013.34","journal-title":"Nat Rev Nephrol"},{"issue":"23","key":"5380_CR22","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1056\/NEJMoa1310345","volume":"369","author":"A Parsa","year":"2013","unstructured":"Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, Feldman HI, Parekh RS, Kusek JW, Greene TH, Fink JC, Anderson AH, Choi MJ, Wright JT Jr, Lash JP, Freedman BI, Ojo A, Winkler CA, Raj DS, Kopp JB, Kao WHL, He J, Jensvold NG, Tao K, Lipkowitz MS, Appel LJ, CRIC Study Investigators (2013) APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 369(23):2183\u20132196. https:\/\/doi.org\/10.1056\/NEJMoa1310345","journal-title":"N Engl J Med"},{"issue":"1","key":"5380_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55408-2","volume":"16","author":"B Zimmerman","year":"2025","unstructured":"Zimmerman B, Dakin LA, Fortier A, Nanou E, Blasio A, Mann J, Miller H, Fletcher M, Wang T, Nanthakumar S, McCarthy G, Matar C, Matsye P, Wang G, Snyder P, Daniel K, Swamy H, Sullivan K, Bright F, Powers A, Gagnon KJ, Lu F, Paula S, Khare-Pandit S, Henry L, Hamel M, Denis F, Nicolas O, Hariparsad N, Kumar S, Proctor J, Senter T, Furey B, Bunnage ME (2025) Small molecule APOL1 inhibitors as a precision medicine approach for APOL1-mediated kidney disease. Nat Commun 16(1):167. https:\/\/doi.org\/10.1038\/s41467-024-55408-2","journal-title":"Nat Commun"},{"issue":"11","key":"5380_CR24","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1681\/ASN.0000000000000219","volume":"34","author":"AM Hung","year":"2023","unstructured":"Hung AM, Assimon VA, Chen HC, Yu Z, Vlasschaert C, Triozzi JL, Chan H, Wheless L, Wilson O, Shah SC, Mack T, Thompson T, Matheny ME, Chandrasekar S, Mozaffari SV, Chung CP, Tsao P, Susztak K, Siew ED, Estrada K, Gaziano JM, Graham RR, Tao R, Hoek M, Robinson-Cohen C, Green EM, Bick AG, Million Veteran Program (2023) Genetic inhibition of APOL1 pore-forming function prevents APOL1-mediated kidney disease. J Am Soc Nephrol 34(11):1889\u20131899. https:\/\/doi.org\/10.1681\/ASN.0000000000000219","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"5380_CR25","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.2215\/CJN.01330214","volume":"9","author":"BI Freedman","year":"2014","unstructured":"Freedman BI, Skorecki K (2014) Gene-gene and gene-environment interactions in apolipoprotein L1 gene-associated nephropathy. Clin J Am Soc Nephrol 9(11):2006\u20132013. https:\/\/doi.org\/10.2215\/CJN.01330214","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"5380_CR26","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1053\/j.ackd.2014.06.005","volume":"21","author":"S Limou","year":"2014","unstructured":"Limou S, Nelson GW, Kopp JB, Winkler CA (2014) APOL1 kidney risk alleles: population genetics and disease associations. Adv Chronic Kidney Dis 21(5):426\u2013433. https:\/\/doi.org\/10.1053\/j.ackd.2014.06.005","journal-title":"Adv Chronic Kidney Dis"},{"issue":"9","key":"5380_CR27","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1681\/ASN.2013010113","volume":"24","author":"MC Foster","year":"2013","unstructured":"Foster MC, Coresh J, Fornage M, Astor BC, Grams M, Franceschini N, Boerwinkle E, Parekh RS, Kao WH (2013) APOL1 variants associate with increased risk of CKD among African Americans. J Am Soc Nephrol 24(9):1484\u20131491. https:\/\/doi.org\/10.1681\/ASN.2013010113","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"5380_CR28","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1590\/2175-8239-JBN-2017-0033","volume":"40","author":"TA Siemens","year":"2018","unstructured":"Siemens TA, Riella MC, Moraes TP, Riella CV (2018) APOL1 risk variants and kidney disease: what we know so far. J Bras Nefrol 40(4):388\u2013402. https:\/\/doi.org\/10.1590\/2175-8239-JBN-2017-0033","journal-title":"J Bras Nefrol"},{"issue":"R1","key":"5380_CR29","doi-asserted-by":"publisher","first-page":"R129","DOI":"10.1093\/hmg\/ddab024","volume":"30","author":"AA Yusuf","year":"2021","unstructured":"Yusuf AA, Govender MA, Brandenburg JT, Winkler CA (2021) Kidney disease and APOL1. Hum Mol Genet 30(R1):R129\u2013R137. https:\/\/doi.org\/10.1093\/hmg\/ddab024","journal-title":"Hum Mol Genet"},{"issue":"11","key":"5380_CR30","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1681\/ASN.2011040388","volume":"22","author":"JB Kopp","year":"2011","unstructured":"Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, Friedman D, Briggs W, Dart R, Korbet S, Mokrzycki MH, Kimmel PL, Limou S, Ahuja TS, Berns JS, Fryc J, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Vlahov D, Pollak M, Winkler CA (2011) APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 22(11):2129\u20132137. https:\/\/doi.org\/10.1681\/ASN.2011040388","journal-title":"J Am Soc Nephrol"},{"issue":"19","key":"5380_CR31","doi-asserted-by":"publisher","first-page":"5586","DOI":"10.1111\/febs.15677","volume":"288","author":"R Goyal","year":"2021","unstructured":"Goyal R, Singhal PC (2021) APOL1 risk variants and the development of HIV-associated nephropathy. FEBS J 288(19):5586\u20135597. https:\/\/doi.org\/10.1111\/febs.15677","journal-title":"FEBS J"},{"issue":"3","key":"5380_CR32","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/ki.2012.129","volume":"82","author":"T Hays","year":"2012","unstructured":"Hays T, Wyatt CM (2012) APOL1 variants in HIV-associated nephropathy: just one piece of the puzzle. Kidney Int 82(3):259\u2013260. https:\/\/doi.org\/10.1038\/ki.2012.129","journal-title":"Kidney Int"},{"issue":"2","key":"5380_CR33","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/ki.2014.270","volume":"87","author":"B Nichols","year":"2015","unstructured":"Nichols B, Jog P, Lee JH, Blackler D, Wilmot M, D\u2019Agati V, Markowitz G, Kopp JB, Alper SL, Pollak MR, Friedman DJ (2015) Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1. Kidney Int 87(2):332\u2013342. https:\/\/doi.org\/10.1038\/ki.2014.270","journal-title":"Kidney Int"},{"issue":"3","key":"5380_CR34","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/j.1365-2141.2011.08832.x","volume":"155","author":"AE Ashley-Koch","year":"2011","unstructured":"Ashley-Koch AE, Okocha EC, Garrett ME, Soldano K, De Castro LM, Jonassaint JC, Orringer EP, Eckman JR, Telen MJ (2011) MYH9 and APOL1 are both associated with sickle cell disease nephropathy. Br J Haematol 155(3):386\u2013394. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08832.x","journal-title":"Br J Haematol"},{"issue":"8","key":"5380_CR35","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1681\/ASN.2020050558","volume":"31","author":"H Wu","year":"2020","unstructured":"Wu H, Larsen CP, Hernandez-Arroyo CF, Mohamed MMB, Caza T, Sharshir M, Chughtai A, Xie L, Gimenez JM, Sandow TA, Lusco MA, Yang H, Acheampong E, Rosales IA, Colvin RB, Fogo AB, Velez JCQ (2020) AKI and collapsing glomerulopathy associated with COVID-19 and APOL1 high-risk genotype. J Am Soc Nephrol 31(8):1688\u20131695. https:\/\/doi.org\/10.1681\/ASN.2020050558","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"5380_CR36","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1681\/ASN.2012121180","volume":"24","author":"CP Larsen","year":"2013","unstructured":"Larsen CP, Beggs ML, Saeed M, Walker PD (2013) Apolipoprotein L1 risk variants associate with systemic lupus erythematosus-associated collapsing glomerulopathy. J Am Soc Nephrol 24(5):722\u2013725. https:\/\/doi.org\/10.1681\/ASN.2012121180","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"5380_CR37","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1161\/ATVBAHA.117.309384","volume":"37","author":"TK Chen","year":"2017","unstructured":"Chen TK, Appel LJ, Grams ME, Tin A, Choi MJ, Lipkowitz MS, Winkler CA, Estrella MM (2017) APOL1 risk variants and cardiovascular disease: results from the AASK (African american study of kidney disease and hypertension). Arterioscler Thromb Vasc Biol 37(9):1765\u20131769. https:\/\/doi.org\/10.1161\/ATVBAHA.117.309384","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"5380_CR38","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/art.38220","volume":"66","author":"BI Freedman","year":"2014","unstructured":"Freedman BI, Langefeld CD, Andringa KK, Croker JA, Williams AH, Garner NE, Birmingham DJ, Hebert LA, Hicks PJ, Segal MS, Edberg JC, Brown EE, Alarc\u00f3n GS, Costenbader KH, Comeau ME, Criswell LA, Harley JB, James JA, Kamen DL, Lim SS, Merrill JT, Sivils KL, Niewold TB, Patel NM, Petri M, Ramsey\u2010Goldman R, Reveille JD, Salmon JE, Tsao BP, Gibson KL, Byers JR, Vinnikova AK, Lea JP, Julian BA, Kimberly RP, Lupus Nephritis\u2013End\u2010Stage Renal Disease Consortium (2014) End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol 66(2):390\u2013396. https:\/\/doi.org\/10.1002\/art.38220","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"5380_CR39","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/nm.4362","volume":"23","author":"SS Hayek","year":"2017","unstructured":"Hayek SS, Koh KH, Grams ME, Wei C, Ko YA, Li J, Samelko B, Lee H, Dande RR, Lee HW, Hahm E, Peev V, Tracy M, Tardi NJ, Gupta V, Altintas MM, Garborcauskas G, Stojanovic N, Winkler CA, Lipkowitz MS, Tin A, Inker LA, Levey AS, Zeier M, Freedman BI, Kopp JB, Skorecki K, Coresh J, Quyyumi AA, Sever S, Reiser J (2017) A tripartite complex of suPAR, APOL1 risk variants and \u03b1v\u03b23 integrin on podocytes mediates chronic kidney disease. Nat Med 23(8):945\u2013953. https:\/\/doi.org\/10.1038\/nm.4362","journal-title":"Nat Med"},{"issue":"3","key":"5380_CR40","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/ndt\/gft423","volume":"29","author":"J Divers","year":"2014","unstructured":"Divers J, Palmer ND, Lu L, Langefeld CD, Rocco MV, Hicks PJ, Murea M, Ma L, Bowden DW, Freedman BI (2014) Gene-gene interactions in APOL1-associated nephropathy. Nephrol Dial Transplant 29(3):587\u2013594. https:\/\/doi.org\/10.1093\/ndt\/gft423","journal-title":"Nephrol Dial Transplant"},{"issue":"5 Suppl 1","key":"5380_CR41","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1053\/j.ajkd.2018.06.020","volume":"72","author":"BI Freedman","year":"2018","unstructured":"Freedman BI, Limou S, Ma L, Kopp JB (2018) APOL1-Associated nephropathy: a key contributor to racial disparities in CKD. Am J Kidney Dis 72(5 Suppl 1):S8\u2013S16. https:\/\/doi.org\/10.1053\/j.ajkd.2018.06.020","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"5380_CR42","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/MNH.0000000000000977","volume":"33","author":"O Tabachnikov","year":"2024","unstructured":"Tabachnikov O, Skorecki K, Kruzel-Davila E (2024) APOL1 nephropathy - a population genetics success story. Curr Opin Nephrol Hypertens 33(4):447\u2013455. https:\/\/doi.org\/10.1097\/MNH.0000000000000977","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"8 Suppl","key":"5380_CR43","first-page":"16S","volume":"94","author":"DA Price","year":"2002","unstructured":"Price DA, Crook ED (2002) Kidney disease in African Americans: genetic considerations. J Natl Med Assoc 94(8 Suppl):16S-27S","journal-title":"J Natl Med Assoc"},{"issue":"5","key":"5380_CR44","doi-asserted-by":"publisher","DOI":"10.1172\/JCI172262","volume":"134","author":"S Datta","year":"2024","unstructured":"Datta S, Antonio BM, Zahler NH, Theile JW, Krafte D, Zhang H, Rosenberg PB, Chaves AB, Muoio DM, Zhang G, Silas D, Li G, Soldano K, Nystrom S, Ferreira D, Miller SE, Bain JR, Muehlbauer MJ, Ilkayeva O, Becker TC, Hohmeier H-E, Newgard CB, Olabisi OA (2024) APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease. J Clin Invest 134(5):e172262. https:\/\/doi.org\/10.1172\/JCI172262","journal-title":"J Clin Invest"},{"issue":"11","key":"5380_CR45","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1056\/NEJMoa2202396","volume":"388","author":"O Egbuna","year":"2023","unstructured":"Egbuna O, Zimmerman B, Manos G, Fortier A, Chirieac MC, Dakin LA, Friedman DJ, Bramham K, Campbell K, Knebelmann B, Barisoni L, Falk RJ, Gipson DS, Lipkowitz MS, Ojo A, Bunnage ME, Pollak MR, Altshuler D, Chertow GM, VX19-147-101 Study Group (2023) Inaxaplin for proteinuric kidney disease in persons with two APOL1 variants. N Engl J Med 388(11):969\u2013979. https:\/\/doi.org\/10.1056\/NEJMoa2202396","journal-title":"N Engl J Med"},{"issue":"4","key":"5380_CR46","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nm.4287","volume":"23","author":"P Beckerman","year":"2017","unstructured":"Beckerman P, Bi-Karchin J, Park AS, Qiu C, Dummer PD, Soomro I, Boustany-Kari CM, Pullen SS, Miner JH, Hu CA, Rohacs T, Inoue K, Ishibe S, Saleem MA, Palmer MB, Cuervo AM, Kopp JB, Susztak K (2017) Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice. Nat Med 23(4):429\u2013438. https:\/\/doi.org\/10.1038\/nm.4287","journal-title":"Nat Med"},{"issue":"4","key":"5380_CR47","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1681\/ASN.2016050567","volume":"28","author":"L Ma","year":"2017","unstructured":"Ma L, Chou JW, Snipes JA, Bharadwaj MS, Craddock AL, Cheng D, Weckerle A, Petrovic S, Hicks PJ, Hemal AK, Hawkins GA, Miller LD, Molina AJ, Langefeld CD, Murea M, Parks JS, Freedman BI (2017) APOL1 renal-risk variants induce mitochondrial dysfunction. J Am Soc Nephrol 28(4):1093\u20131105. https:\/\/doi.org\/10.1681\/ASN.2016050567","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"5380_CR48","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.ekir.2020.03.020","volume":"5","author":"L Ma","year":"2020","unstructured":"Ma L, Ainsworth HC, Snipes JA, Murea M, Choi YA, Langefeld CD, Parks JS, Bharadwaj MS, Chou JW, Hemal AK, Petrovic S, Craddock AL, Cheng D, Hawkins GA, Miller LD, Hicks PJ, Saleem MA, Divers J, Molina AJA, Freedman BI (2020) APOL1 kidney-risk variants induce mitochondrial fission. Kidney Int Rep 5(6):891\u2013904. https:\/\/doi.org\/10.1016\/j.ekir.2020.03.020","journal-title":"Kidney Int Rep"},{"key":"5380_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-018-0188-2","volume":"1","author":"K Okamoto","year":"2018","unstructured":"Okamoto K, Rausch JW, Wakashin H, Fu Y, Chung JY, Dummer PD, Shin MK, Chandra P, Suzuki K, Shrivastav S, Rosenberg AZ, Hewitt SM, Ray PE, Noiri E, Le Grice SFJ, Hoek M, Han Z, Winkler CA, Kopp JB (2018) APOL1 risk allele RNA contributes to renal toxicity by activating protein kinase R. Commun Biol 1:188. https:\/\/doi.org\/10.1038\/s42003-018-0188-2","journal-title":"Commun Biol"},{"issue":"11","key":"5380_CR50","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1681\/ASN.2016111220","volume":"28","author":"D Granado","year":"2017","unstructured":"Granado D, M\u00fcller D, Krausel V, Kruzel-Davila E, Schuberth C, Eschborn M, Wedlich-S\u00f6ldner R, Skorecki K, Pavenst\u00e4dt H, Michgehl U, Weide T (2017) Intracellular APOL1 risk variants cause cytotoxicity accompanied by energy depletion. J Am Soc Nephrol 28(11):3227\u20133238. https:\/\/doi.org\/10.1681\/ASN.2016111220","journal-title":"J Am Soc Nephrol"},{"key":"5380_CR51","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1146\/annurev-med-050311-163340","volume":"64","author":"J Reiser","year":"2013","unstructured":"Reiser J, Sever S (2013) Podocyte biology and pathogenesis of kidney disease. Annu Rev Med 64:357\u2013366. https:\/\/doi.org\/10.1146\/annurev-med-050311-163340","journal-title":"Annu Rev Med"},{"issue":"20","key":"5380_CR52","doi-asserted-by":"publisher","DOI":"10.1172\/JCI136329","volume":"131","author":"J Wu","year":"2021","unstructured":"Wu J, Raman A, Coffey NJ, Sheng X, Wahba J, Seasock MJ, Ma Z, Beckerman P, Laczk\u00f3 D, Palmer MB, Kopp JB, Kuo JJ, Pullen SS, Boustany-Kari CM, Linkermann A, Susztak K (2021) The key role of NLRP3 and STING in APOL1-associated podocytopathy. J Clin Invest 131(20):e136329. https:\/\/doi.org\/10.1172\/JCI136329","journal-title":"J Clin Invest"},{"issue":"1","key":"5380_CR53","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12882-025-04687-y","volume":"27","author":"OC Adebayo","year":"2025","unstructured":"Adebayo OC, Okpoli HC, Vriens J, Levtchenko E, Heuvel LVD, Labarque V (2025) APOL1-mediated kidney disease: a narrative review of the lessons learnt from the past 15 years. BMC Nephrol 27(1):60. https:\/\/doi.org\/10.1186\/s12882-025-04687-y","journal-title":"BMC Nephrol"},{"issue":"2","key":"5380_CR54","doi-asserted-by":"publisher","first-page":"F463","DOI":"10.1152\/ajprenal.00233.2019","volume":"317","author":"V Kumar","year":"2019","unstructured":"Kumar V, Singhal PC (2019) APOL1 and kidney cell function. Am J Physiol Renal Physiol 317(2):F463\u2013F477. https:\/\/doi.org\/10.1152\/ajprenal.00233.2019","journal-title":"Am J Physiol Renal Physiol"},{"issue":"13","key":"5380_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/cells14130960","volume":"14","author":"V H\u00f6ffken","year":"2025","unstructured":"H\u00f6ffken V, Braun DA, Pavenst\u00e4dt H, Weide T (2025) A cell biologist\u2019s view on APOL1: what we know and what we still need to address. Cells 14(13):960. https:\/\/doi.org\/10.3390\/cells14130960","journal-title":"Cells"},{"issue":"8","key":"5380_CR56","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.4161\/auto.7066","volume":"4","author":"S Zhaorigetu","year":"2008","unstructured":"Zhaorigetu S, Wan G, Kaini R, Jiang Z, Hu CA (2008) ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death. Autophagy 4(8):1079\u20131082. https:\/\/doi.org\/10.4161\/auto.7066","journal-title":"Autophagy"},{"issue":"3","key":"5380_CR57","doi-asserted-by":"publisher","first-page":"F326","DOI":"10.1152\/ajprenal.00647.2013","volume":"307","author":"X Lan","year":"2014","unstructured":"Lan X, Jhaveri A, Cheng K, Wen H, Saleem MA, Mathieson PW, Mikulak J, Aviram S, Malhotra A, Skorecki K, Singhal PC (2014) APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability. Am J Physiol Renal Physiol 307(3):F326\u2013F336. https:\/\/doi.org\/10.1152\/ajprenal.00647.2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"5380_CR58","doi-asserted-by":"publisher","unstructured":"Kim J, Karel IZ, Song H, Dewalt M, Orwick S, Buelow DR, Lee K, Brodsky SV, Blissett A, Cocucci E, Baker SD, Lin PH, Pabla NS, and Madhavan SM (2025) Genomewide screen identifies peroxisomal role in APOL1 Podocytopathy.\u00a0medRxiv: the preprint server for health sciences, 2025.02.15.25322241. https:\/\/doi.org\/10.1101\/2025.02.15.25322241","DOI":"10.1101\/2025.02.15.25322241"},{"issue":"3","key":"5380_CR59","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1681\/ASN.2016121322","volume":"29","author":"JF O'Toole","year":"2018","unstructured":"O\u2019Toole JF, Schilling W, Kunze D, Madhavan SM, Konieczkowski M, Gu Y, Luo L, Wu Z, Bruggeman LA, Sedor JR (2018) ApoL1 overexpression drives variant-independent cytotoxicity. J Am Soc Nephrol 29(3):869\u2013879. https:\/\/doi.org\/10.1681\/ASN.2016121322","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"5380_CR60","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126124","volume":"4","author":"M Aghajan","year":"2019","unstructured":"Aghajan M, Booten SL, Althage M, Hart CE, Ericsson A, Maxvall I, Ochaba J, Menschik-Lundin A, Hartleib J, Kuntz S, Gattis D, Ahlstr\u00f6m C, Watt AT, Engelhardt JA, Monia BP, Magnone MC, Guo S (2019) Antisense oligonucleotide treatment ameliorates IFN-\u03b3-induced proteinuria in APOL1-transgenic mice. JCI Insight 4(12):e126124. https:\/\/doi.org\/10.1172\/jci.insight.126124","journal-title":"JCI Insight"},{"issue":"1","key":"5380_CR61","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/sclerosis3010006","volume":"3","author":"C Delrue","year":"2025","unstructured":"Delrue C, Speeckaert MM (2025) From gene to clinic: the role of APOL1 in focal segmental glomerulosclerosis. Sclerosis 3(1):6. https:\/\/doi.org\/10.3390\/sclerosis3010006","journal-title":"Sclerosis"},{"issue":"1","key":"5380_CR62","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000529227","volume":"3","author":"MR Pollak","year":"2023","unstructured":"Pollak MR, Friedman DJ (2023) APOL1 and APOL1-associated kidney disease: a common disease, an unusual disease gene - proceedings of the Henry Shavelle professorship. Glomerular Dis 3(1):75\u201387. https:\/\/doi.org\/10.1159\/000529227","journal-title":"Glomerular Dis"},{"issue":"3","key":"5380_CR63","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1097\/MS9.0000000000003051","volume":"87","author":"A Waheed","year":"2025","unstructured":"Waheed A, Gul MH, Naeem R, Qayyum SN, Batool K, Shaukat A, Khan N, Shah SI, Siddiqui AR, Farooq AU, Nasir E, Noori S (2025) Clinical implications of apolipoprotein L1 testing in patients with focal segmental glomerulosclerosis: a review of diagnostic and prognostic implications. Annals Med Surgery 87(3):1543\u20131551. https:\/\/doi.org\/10.1097\/MS9.0000000000003051","journal-title":"Annals Med Surgery"},{"issue":"4","key":"5380_CR64","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1053\/j.akdh.2024.03.008","volume":"31","author":"A Koirala","year":"2024","unstructured":"Koirala A, Akilesh S, Jefferson JA (2024) Collapsing glomerulopathy. Adv Kidney Disease Health 31(4):290\u2013298. https:\/\/doi.org\/10.1053\/j.akdh.2024.03.008","journal-title":"Adv Kidney Disease Health"},{"issue":"1","key":"5380_CR65","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/modpathol.2014.92","volume":"28","author":"CP Larsen","year":"2015","unstructured":"Larsen CP, Beggs ML, Saeed M, Ambruzs JM, Cossey LN, Messias NC, Walker PD, Freedman BI (2015) Histopathologic findings associated with APOL1 risk variants in chronic kidney disease. Mod Pathol 28(1):95\u2013102. https:\/\/doi.org\/10.1038\/modpathol.2014.92","journal-title":"Mod Pathol"},{"issue":"1","key":"5380_CR66","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nrneph.2015.172","volume":"12","author":"BI Freedman","year":"2016","unstructured":"Freedman BI, Cohen AH (2016) Hypertension-attributed nephropathy: what\u2019s in a name. Nat Rev Nephrol 12(1):27\u201336. https:\/\/doi.org\/10.1038\/nrneph.2015.172","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"5380_CR67","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1053\/j.ackd.2019.01.003","volume":"26","author":"TW Robinson","year":"2019","unstructured":"Robinson TW, Freedman BI (2019) The impact of APOL1 on chronic kidney disease and hypertension. Adv Chronic Kidney Dis 26(2):131\u2013136. https:\/\/doi.org\/10.1053\/j.ackd.2019.01.003","journal-title":"Adv Chronic Kidney Dis"},{"issue":"2","key":"5380_CR68","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/COH.0000000000000784","volume":"18","author":"RKY Hung","year":"2023","unstructured":"Hung RKY, Winkler CA, Post FA (2023) Host factors predisposing to kidney disease in people with HIV. Curr Opin HIV AIDS 18(2):87\u201392. https:\/\/doi.org\/10.1097\/COH.0000000000000784","journal-title":"Curr Opin HIV AIDS"},{"issue":"7","key":"5380_CR69","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1681\/ASN.2020101399","volume":"32","author":"BI Freedman","year":"2021","unstructured":"Freedman BI, Burke W, Divers J, Eberhard L, Gadegbeku CA, Gbadegesin R, Hall ME, Jones-Smith T, Knight R, Kopp JB, Kovesdy CP, Norris KC, Olabisi OA, Roberts GV, Sedor JR, Blacksher E (2021) Diagnosis, education, and care of patients with APOL1-associated nephropathy: a Delphi consensus and systematic review. J Am Soc Nephrol 32(7):1765\u20131778. https:\/\/doi.org\/10.1681\/ASN.2020101399","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"5380_CR70","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41577-022-00816-y","volume":"23","author":"HJ Anders","year":"2023","unstructured":"Anders HJ, Kitching AR, Leung N, Romagnani P (2023) Glomerulonephritis: immunopathogenesis and immunotherapy. Nat Rev Immunol 23(7):453\u2013471. https:\/\/doi.org\/10.1038\/s41577-022-00816-y","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"5380_CR71","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1681\/ASN.0000000000000367","volume":"35","author":"E Pays","year":"2024","unstructured":"Pays E (2024) The mechanism of kidney disease due to APOL1 risk variants: involvement of two distinct processes. J Am Soc Nephrol 35(6):818\u2013821. https:\/\/doi.org\/10.1681\/ASN.0000000000000367","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"5380_CR72","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/nrneph.2017.97","volume":"13","author":"EF Carney","year":"2017","unstructured":"Carney EF (2017) Chronic kidney disease: role of suPAR in APOL1-associated kidney disease. Nat Rev Nephrol 13(9):514. https:\/\/doi.org\/10.1038\/nrneph.2017.97","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"5380_CR73","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/j.1600-6143.2011.03513.x","volume":"11","author":"AM Reeves-Daniel","year":"2011","unstructured":"Reeves-Daniel AM, DePalma JA, Bleyer AJ, Rocco MV, Murea M, Adams PL, Langefeld CD, Bowden DW, Hicks PJ, Stratta RJ, Lin JJ, Kiger DF, Gautreaux MD, Divers J, Freedman BI (2011) The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant 11(5):1025\u20131030. https:\/\/doi.org\/10.1111\/j.1600-6143.2011.03513.x","journal-title":"Am J Transplant"},{"issue":"1","key":"5380_CR74","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/TP.0000000000000969","volume":"100","author":"BI Freedman","year":"2016","unstructured":"Freedman BI, Pastan SO, Israni AK, Schladt D, Julian BA, Gautreaux MD, Hauptfeld V, Bray RA, Gebel HM, Kirk AD, Gaston RS, Rogers J, Farney AC, Orlando G, Stratta RJ, Mohan S, Ma L, Langefeld CD, Bowden DW, Hicks PJ, Palmer ND, Palanisamy A, Reeves-Daniel AM, Brown WM, Divers J (2016) APOL1 genotype and kidney transplantation outcomes from deceased African American donors. Transplantation 100(1):194\u2013202. https:\/\/doi.org\/10.1097\/TP.0000000000000969","journal-title":"Transplantation"},{"issue":"3","key":"5380_CR75","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ekir.2019.11.022","volume":"5","author":"BI Freedman","year":"2019","unstructured":"Freedman BI, Moxey-Mims MM, Alexander AA, Astor BC, Birdwell KA, Bowden DW, Bowen G, Bromberg J, Craven TE, Dadhania DM, Divers J, Doshi MD, Eidbo E, Fornoni A, Gautreaux MD, Gbadegesin RA, Gee PO, Guerra G, Hsu CY, Iltis AS, Hsu C, Jefferson N, Julian BA, Klassen DK, Koty PP, Langefeld CD, Lentine KL, Ma L, Mannon RB, Menon MC, Mohan S, Moore JB, Murphy B, Newell KA, Odim J, Ortigosa-Goggins M, Palmer ND, Park M, Parsa A, Pastan SO, Poggio ED, Rajapakse N, Reeves-Daniel AM, Rosas SE, Russell LP, Sawinski D, Smith SC, Spainhour M, Stratta RJ, Weir MR, Reboussin DM, Kimmel PL, Brennan DC (2019) APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO): design and rationale. Kidney Int Rep 5(3):278\u2013288. https:\/\/doi.org\/10.1016\/j.ekir.2019.11.022","journal-title":"Kidney Int Rep"},{"issue":"6","key":"5380_CR76","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1093\/ndt\/gfw061","volume":"32","author":"DK Ng","year":"2017","unstructured":"Ng DK, Robertson CC, Woroniecki RP, Limou S, Gillies CE, Reidy KJ, Winkler CA, Hingorani S, Gibson KL, Hjorten R, Sethna CB, Kopp JB, Moxey-Mims M, Furth SL, Warady BA, Kretzler M, Sedor JR, Kaskel FJ, Sampson MG (2017) APOL1-associated glomerular disease among African-American children: a collaboration of the chronic kidney disease in children (CKiD) and Nephrotic Syndrome Study Network (NEPTUNE) cohorts. Nephrol Dial Transpl 32(6):983\u2013990. https:\/\/doi.org\/10.1093\/ndt\/gfw061","journal-title":"Nephrol Dial Transpl"},{"issue":"5","key":"5380_CR77","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/MNH.0000000000000816","volume":"31","author":"DJ Friedman","year":"2022","unstructured":"Friedman DJ, Ma L, Freedman BI (2022) Treatment potential in APOL1-associated nephropathy. Curr Opin Nephrol Hypertens 31(5):442\u2013448. https:\/\/doi.org\/10.1097\/MNH.0000000000000816","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"6","key":"5380_CR78","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.kint.2024.07.026","volume":"106","author":"E Sula Karreci","year":"2024","unstructured":"Sula Karreci E, Jacas S, Donovan O, Pintye D, Wiley N, Zsengeller ZK, Schlondorff J, Alper SL, Friedman DJ, Pollak MR (2024) Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2. Kidney Int 106(6):1072\u20131085. https:\/\/doi.org\/10.1016\/j.kint.2024.07.026","journal-title":"Kidney Int"},{"issue":"19","key":"5380_CR79","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1001\/jama.2024.2667","volume":"331","author":"T Hopper","year":"2024","unstructured":"Hopper T, Olabisi OA (2024) APOL1-mediated kidney disease. JAMA 331(19):1668\u20131669. https:\/\/doi.org\/10.1001\/jama.2024.2667","journal-title":"JAMA"},{"issue":"1","key":"5380_CR80","doi-asserted-by":"publisher","first-page":"126","DOI":"10.2215\/CJN.0000000000000256","volume":"19","author":"JR Sedor","year":"2024","unstructured":"Sedor JR (2024) APOL1 kidney disease: discovery to targeted therapy in 10 years. Clin J Am Soc Nephrol 19(1):126\u2013128. https:\/\/doi.org\/10.2215\/CJN.0000000000000256","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11S","key":"5380_CR81","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1681\/ASN.20223311S1169c","volume":"33","author":"A Blasio","year":"2022","unstructured":"Blasio A, Sullivan KE, Mann JJ, Wang G, Kumar S, Bright F, Bouillez A, Daniel K, Nanthakumar S, Rosario AA, Aragon Mejia MA, Heighton TF, Nanou E, Proctor J, Furey B, Fortier A, Senter TJ, Dakin L, Zimmerman B (2022) APOL1 inhibitors reverse established proteinuria in an APOL1-mediated kidney disease mouse model: TH-PO442. J Am Soc Nephrol 33(11S):169. https:\/\/doi.org\/10.1681\/ASN.20223311S1169c","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"5380_CR82","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/MNH.0000000000000704","volume":"30","author":"LA Bruggeman","year":"2021","unstructured":"Bruggeman LA, Sedor JR, O\u2019Toole JF (2021) Apolipoprotein L1 and mechanisms of kidney disease susceptibility. Curr Opin Nephrol Hypertens 30(3):317\u2013323. https:\/\/doi.org\/10.1097\/MNH.0000000000000704","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"9","key":"5380_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2025.101062","volume":"7","author":"V Srinivasan","year":"2025","unstructured":"Srinivasan V, So PN, Kwakyi EP, Lerma EV, Wiegley N (2025) APOL1 mediated kidney disease: a review and look toward the future. Kidney Med 7(9):101062. https:\/\/doi.org\/10.1016\/j.xkme.2025.101062","journal-title":"Kidney Med"},{"key":"5380_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43020-9","volume":"14","author":"Y Gupta","year":"2023","unstructured":"Gupta Y, Friedman DJ, McNulty MT, Khan A, Sampson MG, Nephrotic Syndrome Study Network (2023) Strong protective effect of the APOL1 p.N264K variant against G2-associated focal segmental glomerulosclerosis and kidney disease. Nat Commun 14:7836. https:\/\/doi.org\/10.1038\/s41467-023-43020-9","journal-title":"Nat Commun"},{"issue":"11","key":"5380_CR85","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1681\/ASN.2014050469","volume":"26","author":"AN Kasembeli","year":"2015","unstructured":"Kasembeli AN, Duarte R, Ramsay M, Mosiane P, Dickens C, Dix-Peek T, Limou S, Sezgin E, Nelson GW, Fogo AB, Goetsch S, Kopp JB, Winkler CA, Naicker S (2015) APOL1 risk variants are strongly associated with HIV-associated nephropathy in Black South Africans. J Am Soc Nephrol 26(11):2882\u20132890. https:\/\/doi.org\/10.1681\/ASN.2014050469","journal-title":"J Am Soc Nephrol"},{"key":"5380_CR86","unstructured":"Vertex Pharmaceuticals Incorporated. (2026, August 3). Vertex reports second quarter 2026 financial results [Press release]. Retrieved 25 August 2026 from https:\/\/news.vrtx.com\/news-releases\/news-release-details\/vertex-reports-second-quarter-2026-financial-results"},{"key":"5380_CR87","unstructured":"Maze Therapeutics, Inc. (2026, March 25). Maze Therapeutics announces positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating the first clinical proof of concept in patients with broad APOL1-mediated kidney disease [Press release]. Retrieved 25 August 2026 from https:\/\/ir.mazetx.com\/news-releases\/news-release-details\/maze-therapeutics-announces-positive-topline-data-phase-2"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05380-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05380-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05380-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:44:48Z","timestamp":1788878688000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05380-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":87,"alternative-id":["5380"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05380-1","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"24 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Clinical trial","group":{"name":"EthicsHeading","label":"Declarations"}}]}}